Trial Profile
A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms BEGIN: SWITCH 2; SWITCH 2
- Sponsors Novo Nordisk
- 28 Oct 2019 Results evaluating the IHSG level 2 definition by applying it to a series of clinical trials in patients with type 1 or type 2 diabetes published in the Diabetes Care
- 05 Oct 2018 Results of a post hoc analysis from SWITCH 1 and 2 trials presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 02 Oct 2018 Results of post hoc analysis from SWITCH 1 and 2 trials presented in a Novo Nordisk media release.